Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) included InnoCare's ICP‑B794 and Hiteck Biological's Aponermin in the "Care Program – Extension" pilot project, while Genhouse…

September 28, 2026

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

September 24, 2026

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

September 21, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

CDE NMPA

CDE Reports 35.84% Increase in Drug Filings for 2023 with Focus on Innovation and Rare Diseases

October 23, 2024

CRO / CMO / CDMO Genomics / NGS

US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions

January 31, 2025

Cancer NHC (NHFPC)

China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates